RBC Capital raised the firm’s price target on Humana (HUM) to $322 from $283 and keeps an Outperform rating on the shares. The management has emphasized 2028 as a key target for stars bonus recovery at Humana’s 2025 Investor Day, but the firm is encouraged by the management’s optimistic tone over strong NPS scores, internal patient experience surveys, and member efficacy as evidenced by strong membership recapture, the analyst tells investors in a research note. These indicate better than expected positioning in the wake of significant plan design changes into 2025, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Quipt Home Medical price target raised to $2.30 from $1.70 at Canaccord
- Simon Property, Humana partner on health initiative
- Judges reject 2 cases challenging Medicare negotiation, The Hill reports
- Humana: Balancing Strong Performance with Uncertainty and Risks – A Hold Recommendation
- Exact Sciences expands colorectal cancer screening partnership with Humana